



Suite 518, Level 5  
165-167 Phillip Street  
Sydney NSW Australia 2000  
PO Box H100  
Australia Square NSW Australia 1215  
www.mmjgh.com.au  
info@mmjgh.com.au

## ASX RELEASE

13 November 2018

### MediPharm Labs receives sales licence

**MMJ Group Holdings Limited (ASX: MMJ) ("MMJ")** is pleased to attach a copy of a news release by MediPharm Labs Inc ("MediPharm Labs") (TSX-V: LABS) confirming that it has been issued a sales licence by Health Canada.

MMJ owns 5.2 million shares and 2.9 million warrants (exercisable at CAD\$1.20 per share by October 2020) in MediPharm Labs.

-----

#### Investor and Media Enquiries

Jason Conroy  
Chief Executive Officer

#### About MMJ

*MMJ Group Holdings Limited (ABN 91 601 236 417) is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: <https://www.mmjgh.com.au/investors/>*

#### Important Notice

*This announcement contains reference to certain intentions, expectations, future plans, strategy and prospects of MMJ. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of MMJ may be influenced by a number of factors, many of which are outside the control of MMJ. No representation or warranty, express or implied, is made by MMJ, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause MMJ's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. MMJ does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in MMJ. This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). MMJ's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.*



## MediPharm Labs Corp. Receives Sales Licence from Health Canada

TORONTO, Nov. 12, 2018 -- MediPharm Labs Corp. ("**MediPharm Labs**" or the "**Company**") (TSXV: LABS) is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc., has received its sales licence from Health Canada (the "**Sales Licence**") pursuant to the *Cannabis Act*. The Sales Licence relates to the Company's wholly-owned laboratory and manufacturing facilities in Barrie, Ontario.

"This Sales Licence represents a significant milestone for MediPharm Labs and a key component of our strategy to be a producer of cannabis concentrates at a globally-recognized quality standard, while also being focused on revenues, profitability and value to our shareholders, partners and constituents," says Pat McCutcheon, co-founder and CEO of MediPharm Labs.

A first-mover in cannabis extraction and purification in Canada, MediPharm Labs has invested in an expert team, customized state-of-the-art technology, proprietary methodologies and purpose-built facilities to deliver pharmaceutical-grade and precisely dosable cannabis oils and cannabis concentrates for advanced derivative products. Purified cannabis concentrates have emerged as a preferred basis for consumption and are also the critical elements for isolates and infused products for both the medical and adult use markets where legal globally. MediPharm Labs has been actively building an inventory of specialized cannabis concentrates and isolates in anticipation of receiving its licence, to serve both the medical cannabis and adult-use markets in Canada.

After having obtained its Sales Licence from Health Canada, MediPharm Labs is positioned to fulfill its role in the Canadian cannabis supply chain by delivering advanced oil strategies to its previously announced, innovative and well-established industry partners:

- MediPharm Labs has one of only 32 supply agreements with the [Ontario Cannabis Stores](#)
- The Company has signed four multi-year cannabis concentrate program agreements with partner licensed cultivators:
  - 3-year agreement with [Emerald Therapeutics Inc.](#) (TSXV: EMH – OTCQX: EMHTF) as announced on October 10, 2018
  - 3-year agreement with [INDIVA Limited](#) (TSXV: NDVA) as announced on September 4, 2018
  - 1-year agreement with [Bonify](#) (6779264 Manitoba Inc.) as announced on August 2, 2018
  - 3-year agreement with [James E. Wagner Cultivation Corp](#) (TSXV: JWCA) as announced July 31, 2018
- MediPharm Labs has a 1,200 kg supply agreement with [UP Cannabis Inc.](#) (TSXV: HIP) as announced on September 24, 2018
- Through JV "[Garden Variety](#)", the Company expects to supply four future retail stores in Manitoba that have received provincial approval for bricks and mortar stores as announced on August 22, 2018

### **MediPharm Labs has completed the purification and production of over 180,000 g of cannabis extract.**

MediPharm Labs is research-driven and focused on downstream secondary extraction methodology, distillation and cannabinoid isolation and purification. MediPharm Labs currently operates one of the largest cannabis concentrate manufacturing facilities in Canada and is built to cGMP (current Good Manufacturing Practices) and ISO standards. Leveraging MediPharm Lab's proprietary pharmaceutical manufacturing expertise, the Company currently has Phase 1 capacity to process over 100,000 kg of dry cannabis per year. With Phase 2 funded and expected to be completed by the end of Q2 2019, the Company anticipates that its processing capacity will more than double to up to 250,000 kg annually upon the completion of such expansion.

A photo accompanying this announcement is available at <http://www.globenewswire.com/NewsRoom/AttachmentNg/d4559661-f73d-4ed5-84d8-1ad3f4502eaf>

### **About MediPharm Labs Corp.**

MediPharm Labs, through its subsidiary, is a pioneer in the cannabis industry and has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the *Access to Cannabis for Medical Purposes Regulations (ACMPR)* without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to work with its established, Health Canada-approved cultivation partners to produce pharmaceutical-grade cannabis oil with a competitive advantage. MediPharm Labs is research-driven and focused on

downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. MediPharm Labs, through its subsidiary, provides B2B contract processing of cannabis to Canadian authorized licensed producers and appropriate international growers, supplying integrity-assured cannabis oil to qualified companies for sale under their own brand.

MediPharm Labs will supply raw materials, formulations, processing and packaging for the creation of ready-to-sell advanced derivative products. Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has also completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.

#### **Further Information**

For additional information, please see the Company's website at [www.medipharmlabs.com](http://www.medipharmlabs.com) or contact:

#### **Pat McCutcheon, CEO and President of MediPharm Labs**

Phone: 705-719-7425 ext. 216

Email: [investors@medipharmlabs.com](mailto:investors@medipharmlabs.com)

***Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.***

#### **CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION**

*This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, the Company's joint venture in Manitoba, the expected completion date of the Company's expansion, anticipated processing capacities, and operations in Australia. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; and the delay or failure to receive regulatory approvals. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, the Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.*